Your browser doesn't support javascript.
loading
Flares in patients with systemic lupus erythematosus.
McElhone, Kathleen; Abbott, Janice; Hurley, Margaret; Burnell, Jane; Lanyon, Peter; Rahman, Anisur; Yee, Chee-Seng; Akil, Mohammed; Bruce, Ian N; Ahmad, Yasmeen; Gordon, Caroline; Teh, Lee-Suan.
Afiliação
  • McElhone K; Department of Rheumatology, Royal Blackburn Hospital, Haslingden Road, Blackburn.
  • Abbott J; School of Psychology.
  • Hurley M; Faculty of Health and Wellbeing, University of Central Lancashire, Preston.
  • Burnell J; Faculty of Health and Wellbeing, University of Central Lancashire, Preston.
  • Lanyon P; Rheumatology, Nottingham University Hospitals NHS Trust.
  • Rahman A; Epidemiology and Public Health, University of Nottingham, Nottingham.
  • Yee CS; NIHR Nottingham Biomedical Research Centre, Nottingham.
  • Akil M; Centre for Rheumatology Research, University College London, The Rayne Building, 4th Floor, 5 University Street, London.
  • Bruce IN; Department of Rheumatology, Doncaster Royal Infirmary, Armthorpe Road, Doncaster.
  • Ahmad Y; Department of Rheumatology, Royal Hallamshire Hospital, Glossop Road, Sheffield.
  • Gordon C; Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester.
  • Teh LS; Peter Maddison Rheumatology Centre, Betsi Cadwaldr University Health Board, Llandudno Hospital, Llandudno, Conwy.
Rheumatology (Oxford) ; 60(7): 3262-3267, 2021 07 01.
Article em En | MEDLINE | ID: mdl-33325488
ABSTRACT

OBJECTIVE:

SLE is characterized by relapses and remissions. We aimed to describe the frequency, type and time to flare in a cohort of SLE patients.

METHODS:

SLE patients with one or more 'A' or 'B' BILAG-2004 systems meeting flare criteria ('new' or 'worse' items) and requiring an increase in immunosuppression were recruited from nine UK centres and assessed at baseline and monthly for 9 months. Subsequent flares were defined as severe (any 'A' irrespective of number of 'B' flares), moderate (two or more 'B' without any 'A' flares) and mild (one 'B').

RESULTS:

Of the 100 patients, 94% were female, 61% White Caucasians, mean age (s.d.) was 40.7 years (12.7) and mean disease duration (s.d.) was 9.3 years (8.1). A total of 195 flares re-occurred in 76 patients over 781 monthly assessments (flare rate of 0.25/patient-month). There were 37 severe flares, 32 moderate flares and 126 mild flares. By 1 month, 22% had a mild/moderate/severe flare and 22% had a severe flare by 7 months. The median time to any 'A' or 'B' flare was 4 months. Severe/moderate flares tended to be in the system(s) affected at baseline, whereas mild flares could affect any system.

CONCLUSION:

. In a population with active SLE we observed an ongoing rate of flares from early in the follow-up period with moderate-severe flares being due to an inability to fully control the disease. This real-world population study demonstrates the limitations of current treatments and provides a useful reference population from which to inform future clinical trial design.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exacerbação dos Sintomas / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exacerbação dos Sintomas / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article